Aggressive Angiomyxoma of the Perineum: A Rare Case Entity and Literature Review

Sumit Pandita¹ Irfan Bashir¹ Manish Sharma¹ Swarnita Sahu¹

¹Department of Radiation Oncology, Batra Hospital and Medical Research Centre, New Delhi, India

Address for correspondence Sumit Pandita, DNB, Department of Radiation Oncology, Batra Hospital and Medical Research Centre, Tuglukabad, New Delhi 110062, India (e-mail: sumitv.2010@rediffmail.com).

Asian J Oncol 2019;5:78–81

Abstract

Keywords

- aggressive angiomyxoma
- radiotherapy
- hormonal therapy

Angiomyxomas are soft tissue tumors that are exceedingly rare with very few cases described in literature. They are classified into a less aggressive superficial variant and a deeper aggressive variant commonly called aggressive angiomyxomas (AA). The cross-sectional imaging, particularly magnetic resonance imaging (MRI), plays an essential role in the diagnosis and management of AA. We report a rare case of Aggressive angiomyxoma in a 28-year-old female.

Introduction

Aggressive angiomyxoma (AA) is a very rare soft tissue mesenchymal tumor, typically found in the perineum of females in reproductive age group.¹ Commonly, the tumor simulates as a Bartholin's cyst, abscess or hernia because most patients complain of pain in the perineum, labia, or pelvis.² It grows slowly as a painless solid mass with unclear borders and the AA often infiltrates the deep tissues.³ Even if the tumor infiltrates the bladder, rectum, retroperitoneum, pelvic bone, or levator ani muscle, the patients are often asymptomatic.^{4,5} Surgical excision is the treatment of choice for AA; however, there is a high rate of recurrence.⁶ The local recurrence rate is 25 to 47% after surgical excision.⁷ Complete surgical excision of these tumors is often difficult because of their resemblance to normal tissue.⁸ Although angiomyxoma belongs to a category of neoplasms considered to be radioresistant,⁹ adjuvant radiotherapy (RT) has been reported to be effective in preventing recurrences.¹⁰

Case Report

A 28-year-old healthy woman presented with a 4-year history of a painless swelling on the right side of labia majora. The swelling was gradually increasing in size. There was no history of discharge, difficulty in defecation or urination. On physical examination, the patient was not pale or jaundiced, and the examination of head, neck, chest, and abdomen was unremarkable. Local examination of the perineal region

revealed large soft cystic swelling which was nontender on palpation. Contrast-enhanced computed tomography (CECT) scan of the pelvic region revealed a well-defined long segment heterogeneous density lesion measuring 11 cm × 5 cm with central cystic areas extending from right pararectal space up to labia majora. Lesion was closely abutting the vagina with ill-defined intervening fat planes. No definitive communication with gut loop was seen. The case was discussed in the tumor board of our hospital and the patient underwent wide-local excision of the perineal mass. The gross histopathological examination of the surgical specimen showed a externally bosselated gray–brown mass measuring 12 cm × 9 cm × 3 cm. Cut-section of the specimen revealed gray–white soft tissue with mucoid areas. Microscopic examination showed features of AA entrapping the adjacent skeletal muscle fibers. The deep resection margin was involved. Sections from the skin flap were also involved by tumor. The routine hematoxylin and eosin–stained sections examined from the tumor showed low to moderate cellularity with small, stellate, and spindle cells embedded in loosely collagenous myxomatous matrix containing scattered vessels of varying calibre. The lesion was seen infiltrating between skeletal muscle bundles. No mitosis was seen (► Fig. 1A). On immunohistochemistry, tumor cells were strongly positive for vimentin (► Fig. 1B), estrogen (► Fig. 1C), progesterone (► Fig. 1D), desmin (► Fig. 1E), and negative for CD 34 (► Fig. 1F), smooth muscle antigen (SMA), and S-100.

In view of positive margin status, patient was treated with adjuvant RT to the postoperative bed to a dose of 50 Gy

received
September 20, 2019
accepted
October 15, 2019

DOI <https://doi.org/10.1055/s-0039-3400711>
ISSN 2454-6798.

©2019 Spring Hope Cancer
Foundation & Young Oncologist
Group of Asia

License terms

Fig. 1 (A) Section showing low-to-moderate cellularity with small, stellate, and spindled cells embedded in loosely collagenous myxedematous matrix containing scattered vessels of varying calibre. No mitosis seen (H&E, $\times 40$). (B) Immunohistochemical analysis showed that tumor cells are positive for vimentin. (C) Estrogen receptor immunostatin is positive in tumor cells. (D) Progesterone receptor (PR) immunostatin is positive in tumor cells. (E) Desmin immunostatin is positive in tumor cells. (F) Tumor cells are negative for CD-34 marker.

in 25 fractions, 2 Gy per fraction, one fraction per day over a period of 5 weeks. A volumetric modulated arc therapy (VMAT) plan was generated to optimize dose distribution delivering maximum dose to the target volume and doses to the organs at risk were within acceptable limits (**► Fig. 2**). Treatment was delivered under daily image guidance.

During treatment, the patient experienced grade-1 dermatitis of the right intragluteal fold which was managed symptomatically. After completion of RT, patient was started on adjuvant tamoxifen 20 mg tablet daily. At 3-month follow-up, the skin reactions were healed and CECT pelvis showed postradiotherapy changes with no evidence of any recurrence.

Discussion

Although AA is a rare entity, it is important to be aware of its clinical features. The initial presentation is often a painless, asymptomatic perineal, or vulvar nodule. Overlying skin may appear normal, and clinicians may mistake AA for a benign

entity. The mass may be discovered upon routine gynecologic examination or by the patient herself. Because of the rarity of the AA, preoperative diagnosis is often difficult and a lot of cases are diagnosed on histological findings after the surgical excision.^{11,12} Macroscopically the surface of tumor is smooth, partially or completely encapsulated, lobular, with borders that are not well circumscribed.¹¹ Histologically the tumor demonstrates stellate-to-spindle shaped cells distributed sparsely throughout the myxoid stroma and aggregated around blood vessels. Mitotic figures are infrequent and not atypical, and there is no necrosis within the tumor.^{13,14} Immunohistochemistry commonly is positive for CD 34, SMA, desmin, vimentin, estrogen, and progesterone receptors and is typically negative for S-100.^{14,15} For timely diagnosis, it is important to have a high index of suspicion for AA. Misdiagnosis rates have been reported as high as 82%. Fourteen radiological imaging is critical in assessing extent and surgical approach and in surveillance for recurrences. Multiple imaging modalities have been used to evaluate AA preoperatively including ultrasonography (USG), CT scan (as in the

Fig. 2 Axial image of a VMAT plan showing optimal coverage of the planning target volume by 95% of the prescribed dose. VMAT, volumetric modulated arc therapy.

described case) and magnetic resonance imaging (MRI). USG usually demonstrates a cystic or hypoechoic lesion.¹⁵ On CT scan, the tumor may be hypodense to muscle, or may have both cystic and solid components.¹⁵ It has been suggested that MRI may be preferred due to characteristic swirling pattern observed and better depiction of tissue.¹⁵

Surgical management is the gold standard for both diagnosis and treatment of AA due to the aggressive and infiltrative nature of the disease. As it grows, AA tends to displace rather than invade adjacent organs, though invasion does occur in some cases.¹⁶ Complete surgical removal with negative margins is often not achieved in deeper pelvic tumors.¹⁷ Incomplete surgical removal is acceptable when significant morbidity is anticipated with broader excision. Recurrence rates range from 25 to 47%, with 85% recurring within 5 years of initial surgery.⁷ Chemotherapy and RT have at present an undefined and limited role. Although AA is considered to be radioresistant,⁹ adjuvant RT has been reported to be effective in preventing recurrences.¹⁰ There is not a well-established role for RT in the treatment of AA, though there are a few cases described where radiation was utilized pre- or postoperatively to decrease tumor size or minimize risk of recurrence.⁷

AA has been shown to possess estrogen and progesterone receptors, suggesting growth is hormonally responsive. Use of hormone-modulating therapies has shown success in both neoadjuvant and adjuvant modality to prevent recurrence. Both postoperative radiation and GNRH-agonists have demonstrated complete resolution of residual or recurrent tumor growth and will continue to be valuable treatment options in residual and recurrent tumors.^{14,18}

Conclusion

In conclusion, AA is a very rare disease with difficult diagnosis and lack of standard guidelines for treatment. Complete

surgical excision of the tumor seems to be crucial. A multimodal approach is important. Even tumor-free margins do not prevent recurrence. Adjuvant RT has been reported to be effective in preventing local recurrences. Long-term follow-up is important because of repeated local recurrence.

Funding

None.

Conflict of Interest

None declared.

References

- Smith HO, Worrell RV, Smith AY, Dorin MH, Rosenberg RD, Bartow SA. Aggressive angiomyxoma of the female pelvis and perineum: review of the literature. *Gynecol Oncol* 1991;42(1):79–85
- Elchalal U, Lifschitz-Mercer B, Dgani R, Zalel Y. Aggressive angiomyxoma of the vulva. *Gynecol Oncol* 1992;47(2):260–262
- Chen Lm, Schink JC, Panares BN, Barbutto D, Lagasse LD. Resection of a giant aggressive angiomyxoma in the Philippines. *Gynecol Oncol* 1998;70(3):435–439
- Sun Y, Zhu L, Chang X, Chen J, Lang J. Clinicopathological features and treatment analysis of rare aggressive angiomyxoma of the female pelvis and perineum- a retrospective study. *Pathol Oncol Res* 2017;23(1):131–137
- Ribaldone R, Piantanida P, Surico D, Boldorini R, Colombo N, Surico N. Aggressive angiomyxoma of the vulva. *Gynecol Oncol* 2004;95(3):724–728
- Salman MC, Kuzey GM, Dogan NU, Yuce K. Aggressive angiomyxoma of vulva recurring 8 years after initial diagnosis. *Arch Gynecol Obstet* 2009;280(3):485–487
- Sutton BJ, Laudadio J. Aggressive angiomyxoma. *Arch Pathol Lab Med* 2012;136(2):217–221
- Nakamura T, Miura K, Maruo Y, et al. Aggressive angiomyxoma of the perineum originating from the rectal wall. *J Gastroenterol* 2002;37(4):303–308
- Suit H, Spiro I. Radiation treatment of benign mesenchymal disease. *Semin Radiat Oncol* 1999;9(2):171–178

- 10 Nyam DC, Pemberton JH. Large aggressive angiomyxoma of the perineum and pelvis: an alternative approach. Report of a case. *Dis Colon Rectum* 1998;41(4):514–516
- 11 Haldar K, Martinek IE, Kehoe S. Aggressive angiomyxoma: a case series and literature review. *Eur J Surg Oncol* 2010;36(4):335–339
- 12 Pereira P, Melo Abreu E, Cunha TM, Rolim I. Transperineal aggressive angiomyxoma. *BMJ Case Rep* 2017;2017:bcr-2016-217705
- 13 Wang YF, Qian HL, Jin HM. Local recurrent vaginal aggressive angiomyxoma misdiagnosed as cellular angiofibroma: A case report. *Exp Ther Med* 2016;11(5):1893–1895
- 14 Bai HM, Yang JX, Huang HF, et al. Individualized managing strategies of aggressive angiomyxoma of female genital tract and pelvis. *Eur J Surg Oncol* 2013;39(10):1101–1108
- 15 Outwater EK, Marchetto BE, Wagner BJ, Siegelman ES. Aggressive angiomyxoma: findings on CT and MR imaging. *AJR Am J Roentgenol* 1999;172(2):435–438
- 16 Li X, Ye Z. Aggressive angiomyxoma of the pelvis and perineum: a case report and review of the literature. *Abdom Imaging* 2011;36(6):739–741
- 17 Chen H, Zhao H, Xie Y, Jin M. Clinicopathological features and differential diagnosis of aggressive angiomyxoma of the female pelvis: 5 case reports and literature review. *Medicine (Baltimore)* 2017;96(20):e6820
- 18 Shinohara N, Nonomura K, Ishikawa S, Seki H, Koyanagi T. Medical management of recurrent aggressive angiomyxoma with gonadotropin-releasing hormone agonist. *Int J Urol* 2004;11(6):432–435